Effects of transdermal and oral hormone replacement therapies on monocyte chemoattractant protein-1 levels: A randomized clinical trial

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 176, Issue 1, 2014, Pages 50-54

  Taşçi, Tolga ^a   Şükür, Yavuz Emre ^a   Özmen, Batuhan ^a   Atabekoǧlu, Cem Somer ^a   Cengiz, Sevim Dinçer ^a   Koçbulut, Evren ^a   Berker, Bülent ^a   Sönmezer, Murat ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Homocysteine; Hormone replacement therapy; Lipid profile; Monocyte chemoattractant protein 1; Transdermal

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; ESTRADIOL; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; LIPID; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NORETHISTERONE ACETATE; TRIACYLGLYCEROL; DRUG COMBINATION; ESTRADIOL, NORETHINDRONE DRUG COMBINATION; NORETHISTERONE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HORMONE SUBSTITUTION; HUMAN; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MENOPAUSE; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; DRUG COMBINATION; ESTROGEN THERAPY; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; CHEMOKINE CCL2; DRUG COMBINATIONS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HOMOCYSTEINE; HUMANS; MIDDLE AGED; NORETHINDRONE; POSTMENOPAUSE;

EID: 84899416754     PISSN: 03012115     EISSN: 18727654     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2014.02.034     Document Type: Article

References (40)

1. F. Grodstein, and M.J. Stampfer Estrogen for women at varying risk of coronary disease Maturitas 30 1998 19 26
2. S. Hulley, D. Grady, and T. Bush et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group JAMA 280 1998 605 613
3. J.E. Rossouw, G.L. Anderson, and R.L. Prentice et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 333
4. S.R. Salpeter, J.M. Walsh, E. Greyber, and E.E. Salpeter Brief report: coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis J Gen Intern Med 21 2006 363 366
5. W.P. Castelli Cholesterol and lipids in the risk of coronary artery disease - the Framingham Heart Study Can J Cardiol 4 A 1988 5 10A
6. European Society of Hypertension-European Society of Cardiology Guidelines Committee European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension J Hypertens 21 2003 1011 1053
7. S.S. Mangalmurti, and M.H. Davidson The incremental value of lipids and inflammatory biomarkers in determining residual cardiovascular risk Curr Atheroscler Rep 13 2011 373 380
8. V. Chiantera, C.D. Sarti, and F. Fornaro et al. Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels Menopause 10 2003 286 291
9. M. Navab, S.S. Imes, and S.Y. Hama et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein-1 synthesis and is abolished by high density lipoprotein J Clin Invest 88 1991 2039 2046
10. A.D. Luster Chemokines-chemotactic cytokines that mediate inflammation N Engl J Med 338 1998 436 445
11. R.M. Faruqi, and P.E. DiCorleto Mechanisms of monocyte recruitment and accumulation Br Heart J 69 1993 S19 S29
12. J. Niu, and P.E. Kolattukudy Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implications Clin Sci (Lond) 117 2009 95 109
13. N.A. Nelken, S.R. Coughlin, D. Gordon, and J.N. Wilcox Monocyte chemoattractant protein-1 in human atheromatous plaques J Clin Invest 88 1991 1121 1127
14. M. Takeya, T. Yoshimura, E.J. Leonard, and K. Takahashi Detection of monocyte chemoattractant protein-1 in human atherosclerotic lesions by an anti-monocyte chemoattractant protein-1 monoclonal antibody Hum Pathol 24 1993 534 539
15. R.J. Aiello, P.A. Bourassa, and S. Lindsey et al. Monocyte chemotactic protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice Arterioscler Thromb Vasc Biol 19 1999 1518 1525
16. S. Ylä-Herttuala, B.A. Lipton, and M.E. Rosenfeld et al. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions Proc Natl Acad Sci USA 88 1991 5252 5256
17. N.G. Frangogiannis, O. Dewald, and Y. Xia et al. Critical role of monocyte chemoattractant protein-1/CC chemokine ligand 2 in the pathogenesis of ischemic cardiomyopathy Circulation 115 2007 584 592
18. P.E. Kolattukudy, T. Quach, and S. Bergese et al. Myocarditis induced by targeted expression of the MCP-1 gene in murine cardiac muscle Am J Pathol 152 1998 101 111
19. P.E. Kolattukudy, and J. Niu Inflammation, ER stress, autophagy and MCP-1/CCR-2 pathway Circ Res 110 2012 174 189
20. D.A. Smiley, and R.A. Khalil Estrogenic compounds, estrogen receptors and vascular cell signaling in the aging blood vessels Curr Med Chem 16 2009 1863 1867
21. V.B. Gencel, M.M. Benjamin, S.N. Bahou, and R.A. Khalil Vascular effects of phytoestrogens and alternative menopausal hormone therapy in cardiovascular disease Mini Rev Med Chem 12 2012 149 174
22. J. Hintze PASS 11 2011 NCSS, LLC. Kaysville, UT, USA www.ncss.com
23. O.M. Reslan, and R.A. Khalil Vascular effects of estrogenic menopausal hormone therapy Rev Recent Clin Trials 7 2012 47 70
24. E. Seli, T. Pehlivan, B. Selam, J.A. Garcia-Velasco, and A. Arici Estradiol down-regulates MCP-1 expression in human coronary artery endothelial cells Fertil Steril 77 2002 542 547
25. S. Pervin, R. Singh, M.E. Rosenfeld, M. Navab, G. Chaudhuri, and L. Nathan Estradiol suppresses MCP-1 expression in vivo. Implications for atherosclerosis Arterioscler Thromb Vasc Biol 18 1998 1575 1582
26. S. Störk, K. Baumann, C. von Schacky, and P. Angerer The effect of estradiol on MCP-1 serum levels in postmenopausal women Cardiovasc Res 53 2002 642 649
27. J. Gosling, S. Slaymaker, and L. Gu et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B J Clin Invest 103 1999 773 778
28. K.K. Koh, D.K. Jin, and S.H. Yang et al. Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women Circulation 103 2001 1961 1966
29. G.E. Christodoulakos, I.V. Lambrinoudaki, and E.V. Economou et al. Circulating chemoattractants RANTES, negatively related to endogenous androgens, and MCP-1 are differentially suppressed by hormone therapy and raloxifene Atherosclerosis 193 2007 142 150
30. H. Sumino, S. Ichikawa, and Y. Ohyama et al. Effect of transdermal hormone replacement therapy on monocyte chemoattractant protein-1 concentrations and other vascular inflammatory markers and on endothelial function in postmenopausal women Am J Cardiol 96 2005 148 153
31. H. Sumino, S. Ichikawa, and S. Kasama et al. Different effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness and vascular inflammatory markers in postmenopausal women Atherosclerosis 189 2006 436 442
32. T. Yasui, A. Saijo, and H. Uemura et al. Effects of oral and transdermal estrogen therapies on circulating cytokines and chemokines in postmenopausal women with hysterectomy Eur J Endocrinol 161 2009 267 273
33. A.L. Eilertsen, E. Hoibraaten, I. Os, T.O. Andersen, L. Sandvik, and P.M. Sandset The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis Maturitas 52 2005 111 118
34. S. Eviö, A. Tiitinen, U. Turpeinen, and O. Ylikorkala Failure of the combination of sequential oral and transdermal estradiol plus norethisterone acetate to affect plasma homocysteine levels Fertil Steril 74 2000 1080 1083
35. N.H. Farag, B.A. Barshop, and P.J. Mills Effects of estrogen and psychological stress on plasma homocysteine levels Fertil Steril 79 2003 256 260
36. C. Gökkuşu, Z. Özbek, and G. Tata Hormone replacement therapy: relation to homocysteine and prooxidant-antioxidant status in healthy postmenopausal women Arch Gynecol Obstet 285 2012 733 739
37. H. Yüksel, M. Cobanoǧlu, A.R. Odabaşi, S.D. Sezer, M. Küçük, and M. Serter Effects of early initiated oestrogen replacement therapy on plasma homocysteine levels in women in surgically induced menopause Gynecol Endocrinol 27 2011 101 106
38. M.J. Van der Mooren, M.G. Wouters, H.J. Blom, L.A. Schellekens, T.K. Eskes, and R. Rolland Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women Eur J Clin Invest 24 1994 733 736
39. B.W. Walsh, S. Paul, and R.A. Wild et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial J Clin Endocrinol Metab 8 2000 214 218
40. S. Friso, S. Lamon-Fava, H. Jang, E.J. Schaefer, R. Corrocher, and S.W. Choi Oestrogen replacement therapy reduces total plasma homocysteine and enhances genomic DNA methylation in postmenopausal women Br J Nutr 97 2007 617 621